Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial-Reference-Cited by-同舟云学术

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

Published:2014-05 Issue:6 Volume:15 Page:631-639
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wasan Harpreet,Meade Angela M,Adams Richard,Wilson Richard,Pugh Cheryl,Fisher David,Sydes Benjamin,Madi Ayman,Sizer Bruce,Lowdell Charles,Middleton Gary,Butler Rachel,Kaplan Richard,Maughan Tim

Publisher

Elsevier BV

Subject

Oncology

Reference21 articles.

1. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial;Maughan;Lancet,2011

2. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer;Hecht;J Clin Oncol,2009

3. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer;Tol;N Engl J Med,2009

4. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus flox alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study;Tveit;J Clin Oncol,2012

5. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study;Chibaudel;J Clin Oncol,2009

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis;European Journal of Cancer;2024-08

2. Role of blood metabolites in mediating the effect of gut microbiome on the mutated-RAS/BRAF metastatic colorectal cancer-specific survival;International Journal of Colorectal Disease;2024-07-24

3. A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study;Frontiers in Oncology;2024-07-23

4. Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer;World Journal of Gastrointestinal Oncology;2024-06-15

5. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study;Journal of Clinical Oncology;2024-04-10